Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

BioNTech Reaffirms 2024 Revenue Guidance Of €2.5B-€3.1B

Author: Benzinga Newsdesk | May 06, 2024 06:54am

Planned 2024 Financial Year Expenses and Capex

  • R&D expenses: €2.4B-€2.6B
  • SG&A expenses: €700M-€800M
  • Capital expenditures for operating activities: €400M-€500M

Posted In: BNTX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist